MSMatej Skorvanek

Matej Skorvanek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Matej Skorvanek has a total of 788 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Outcome Assessments in Movement Disorders: A Scoping Review of Current Rating Scales and Future Needs Beyond Parkinson's Disease

    by Panagiota Tsitsi, Evita Papathoma, Nirosen Vijiaratnam, Camila Aquino, Stephen R. Duma, Norbert Kovacs, Kigocha Lameck Okeng'O, Aparna Wagle Shukla, Roongroj Bhidayasiri, Alberto J. Espay, et al.

    Background: Clinical outcome assessments (COA) are essential for evaluating symptom severity, treatment response, and disease progression in movement disorders. As clinical knowledge evolves, it is necessary to ensure COAs continued relevance and validity. Objectives: The aims were to provide an updated overview of existing Movement Disorder Society (MDS)–recommended COAs in movement disorders and to identify specific constructs or COAs requiring further revision or validation to inform current clinical practice and research. Methods: The Scientific Evaluation Committee of the MDS‐COA program commissioned a position paper on the current evidentiary state of COAs. A panel of experts conducted a 2‐step review: first, extracting data from previous MDS publications on COA appraisals using a standardized template; second, conducting a scoping review up to May 2026 to identify new COAs or updated validation data in movement disorders. All study designs were considered. Results: Of the 13 constructs identified in movement disorders other than PD, updated reviews are most urgently warranted for tremor and dystonia, given the volume of new evidence, emergence of novel instruments, and expanding therapeutic options. For all remaining constructs, important advances were identified alongside persistent gaps in validation, longitudinal data, and clinical interpretability. Conclusions: The principal challenge in movement‐disorder outcome assessment has shifted from developing new instruments to establishing their comparative validity, responsiveness, and clinical interpretability. Tremor and dystonia have accumulated sufficient new evidence to justify updated MDS reviews, whereas across all constructs the major unmet needs are harmonization of existing measures, longitudinal validation, and integration of patient‐reported and digital outcomes into clinically meaningful assessment frameworks.

  • The Phenomenology of the golfers’ Yips, a Video‐Panel Study

    by Erik van Wensen, Beorn Gerrit Nijenhuis, Esmee van Leeuwen, Roberto Erro, Christos Ganos, Rick Helmich, Hyder Jinnah, Lisette Koens, André Lee, Davide Martino, et al.

    Background: There is ongoing debate on the nature and the phenomenology of the golfers’ yips. Objectives: To clarify the phenomenology of the golfers’ yips, based on assessment of videos by expert neurologists. Methods: A panel of 13 movement disorder neurologists reviewed videos of 15 golfers (10 with and 5 without the yips). Videos showed wrist movements during putting, in three conditions: both hands, right and left hand only. The presence or absence of a movement disorder and its phenomenology was collected via a short questionnaire. Results: The video panel classified the yips as a movement disorder with high overall diagnostic accuracy (0.84[95% CI: 0.71–0.92, p < 0.001]) and significant inter‐rater reliability (Gwet‐AC1 = 0.56, 95% CI: 0.46–0.67, p < 0.001). The phenomenology was predominantly classified as dystonia with significant inter‐rater reliability (Gwet‐AC1 = 0.57, 95% CI: 0.44–0.69, p < 0.001). Conclusions: A panel of expert neurologists considered the golfers’ yips a neurological movement disorder, most consistent with dystonia.

  • Open Access

    Defining the Clinical Phenotypic Ground Truth: Expert Interrater Agreement in Hyperkinetic Movement Disorders

    by Madelein van der Stouwe, Olof Vermeulen, Wieke Eggink, Tove Henriksen, Eavan McGovern, Marenka Smit, Selma Aybek, Agnita Boon, Rick Brandsma, Andres Deik, et al.

    Background: Reliable clinical phenotyping is crucial for diagnosis, treatment, and research in hyperkinetic movement disorders, yet its interrater reliability remains uncertain. Objectives: To quantify interrater agreement in clinical phenotyping of hyperkinetic movement disorders among experts in a large, phenotypically diverse cohort. Methods: Within the NEMO project, 161 patients with hyperkinetic movement disorders underwent standardized video assessments. Each patient was independently classified by three international movement disorders experts in a structured, stepwise procedure. Experts first assessed videos alone, then received clinical history and examination, and finally diagnostic test results. At each step, they assigned primary and secondary phenotypes and rated their diagnostic confidence. Interrater agreement was assessed using Fleiss’ and Cohen's kappa. Results: Across all phenotypes, interrater agreement on the primary phenotype increased with added information ( κ = 0.457 to κ = 0.607). Agreement with the NEMO reference classification similarly improved ( κ = 0.478 to κ = 0.656). Among patients with a single dominant phenotype, agreement reached κ = 0.78. In 93% of cases, at least two out of three experts reached consensus. Agreement was substantially lower in patients with mixed or complex presentations, such as myoclonus‐dystonia and functional movement disorders. Diagnostic certainty rose throughout, though secondary phenotype agreement remained poor. Experts rarely revised initial impressions, suggesting robust pattern recognition but also potential confirmation bias. Conclusions: Movement disorders specialists can reliably identify hyperkinetic phenotypes, even without in‐person assessment. While complex, mixed and functional presentations remain diagnostically challenging, our findings reinforce the value of expert phenotyping in clinical care, training, and research, and provide a benchmark for future studies and computational approaches.

  • Open Access

    KCNQ2 p.(Arg214Trp): systematic review with retrospective analysis and expanding the phenotype

    by Petronela Christova, Miriam Ostrozovicova, Jana Neupauerova, Matej Skorvanek, Zuzana Gdovinova, Eva Feketeova

    Background: Heterozygous pathogenic variants in the KCNQ2 gene underlie a broad phenotypic spectrum ranging from self-limited (familial) neonatal epilepsy (SeLNE) to developmental and epileptic encephalopathy or isolated intellectual disability. The KCNQ2 gene encodes subunits of a voltage-gated potassium channel involved in neuronal excitability, and its mutations are known to have both loss-of-function (LoF) and gain-of-function (GoF) effects, resulting in distinct neurological syndromes. The recurrent missense LoF variant KCNQ2 p.(Arg214Trp) has been previously reported in a single family with a presumed SeLNE phenotype, without detailed adult follow-up and with additional database-reported evidence suggesting a broader phenotype associated with this recurrent variant. Methods: Here, we report a family with two adult carriers of the heterozygous KCNQ2 p.(Arg214Trp) variant identified through whole-exome sequencing, including long-term follow-up into late adulthood. In addition, a literature review of previously reported cases carrying the same recurrent variant was performed. Results: Both individuals presented with early-onset focal epilepsy with a relapsing course, characterized by prolonged seizure-free periods followed by recurrence in adulthood. The proband demonstrated transient motor regression, developmental delay, moderate intellectual disability, ataxia and fine motor impairment. The father exhibited milder cognitive impairment and additional comorbidities in later life. Conclusion: These findings challenge the concept of KCNQ2 p.(Arg214Trp) as a self-limited epilepsy-associated variant and indicate a broader phenotypic spectrum, with persistence of epilepsy and associated neurological and non-neurological comorbidities into adulthood. Our report provides new insights into adult outcomes, aiding in genetic counseling and the long-term management of affected individuals. More extensive studies with larger cohorts carrying this variant are necessary to better define the full phenotypic spectrum and to distinguish comorbidities associated with different etiological factors, including perinatal factors.

  • Open Access

    Update on Genetic Chorea

    by Miriam Ostrozovicova, Matej Skorvanek

    Purpose of Review: Chorea is a symptom of numerous pathophysiologically and clinically heterogeneous genetic conditions. A number of developments have been made in this field over the last years linked to improved genomic testing, large cohort collaborations and improved understanding of the molecular mechanisms. This review aims to provide an update on the new genetic conditions and phenotypes linked to chorea disorders, their modification factors and pathophysiological background. Recent Findings: Several novel genetic conditions have been linked to chorea over the last 3 years, including mutations in FTH1 , NAA60 , ACBD6 or TOR1AIP2 . Also, novel phenotypes have been established and linked to chorea, such as Adult-onset Neurodegeneration in Nucleotide Excision Repair Disorder (NERD-ND). Major advances have been made in understanding of the pathophysiological role of somatic instability in HD. Striatal pallidal neurons (SPNs) with 150–500 + CAG repeats seem to lose positive and then negative features of neuronal identity, de-repress senescence/apoptosis genes, ultimately leading to cell death. Summary: Improved recognition of the genetic background of chorea leads to more effective diagnostic processes, better prognostication and improved personalized treatment. The findings on somatic instability in HD suggest that neurodegeneration in HD is an asynchronous DNA process for >95% of a neuron's life, with majority of neurons in all disease stages having a HTT gene which is not biologically harmful. This has potential major therapeutic implications not only in HD but also in other neurological repeat expansion disorders.

  • Open Access

    Blood transcriptomics reveals a Parkinson's disease signature and heterogeneous prodromal molecular profiles in isolated RBD

    by Peter Artimovic, Kristina Kulcsarova, Marek Kloc, Monika Svecova, Eva Feketeova, Milan Maretta, Petronela Christova, Barbora Zecova, Ema Kerpcarova, Miriama Ostrozovicova, et al.

    Background: Parkinsons disease (PD) has a prolonged prodromal phase, but minimally invasive molecular biomarkers distinguishing manifest PD from prodromal synucleinopathy remain insufficiently characterized. Isolated REM sleep behavior disorder (iRBD) represents a high-risk prodromal condition and provides an opportunity to investigate early blood-based transcriptional alterations. Objective: To identify peripheral blood transcriptomic signatures distinguishing healthy controls (HC), individuals with iRBD, and patients with PD, and to explore whether longitudinal iRBD samples exhibit movement toward a PD-like transcriptional state. Methods: Peripheral blood RNA-seq data were analyzed using harmonized metadata, DESeq2 differential-expression analysis, internally validated machine-learning models, PD-like projection, and integrated biomarker-panel prioritization. Independent baseline samples were used for cross-sectional differential-expression and machine-learning analyses. iRBD follow-up and post-conversion observations were excluded from baseline model development and reserved for exploratory longitudinal analyses. Results: Baseline analyses included 71 independent samples: 20 HC, 31 iRBD, and 20 PD. An additional 19 iRBD follow-up observations, including three post-conversion observations, were available for exploratory analyses. Differential-expression analysis identified 170 FDR-significant genes in PD versus HC and 85 in PD versus iRBD, compared with one FDR-significant gene in iRBD versus HC. Internal machine-learning validation showed stronger discrimination of manifest PD, with a best ROC-AUC of 0.883 for HC versus PD and 0.889 for iRBD versus PD. Discrimination between HC and iRBD was weak, with a best ROC-AUC of 0.584. PD-like projection scores were lowest in HC, highest in PD, and heterogeneous among baseline iRBD samples. Follow-up iRBD samples showed an exploratory upward shift in the mean PD-like projection score. Integrated prioritization produced a 24-gene PD candidate panel and a 24-gene exploratory iRBD panel, with genes in each panel supported by machine-learning feature-stability evidence and differential expression analysis. Conclusions: Manifest PD was associated with a distinct peripheral blood transcriptional signature, whereas iRBD-associated alterations were substantially weaker and more heterogeneous. The prioritized panels represent candidates for independent technical and external validation and should not yet be interpreted as clinically validated diagnostic or prognostic tests.

  • Open Access

    Shared Pathogenic Pathways Between REM Sleep Behavior Disorder and Neurodegenerative and Psychiatric Disorders

    by Zhao Zhang, Emma N. Somerville, Zih-Hua Fang, Lang Liu, Farnaz Asayesh, Jamil Ahmad, Saeid Amiri, Meron Teferra, Pauline Dodet, Isabelle Arnulf, et al.

    Isolated/idiopathic rapid-eye-movement (REM)-Sleep Behavior Disorder (iRBD) is characterized by dream enactment behaviors associated with loss of REM atonia. iRBD is in most cases a prodromal synucleinopathy, and emerging evidence suggests associations between RBD and other neurological and psychiatric conditions. In this study, we performed pathway-based polygenic risk score (PRS) and rare variant burden analyses to examine these potential associations. Pathway-specific PRS were constructed from genome-wide association study summary statistics of five neurodegenerative and seven psychiatric traits across 10 biologically relevant pathway categories, including a total of 279 pathways, in 1,573 iRBD cases and 16,022 controls from the International RBD Study Group and UK Biobank. Rare variant burden tests were performed in 1,264 iRBD cases and 2,581 controls. We identified multiple potential pathways indicating shared polygenic risk between RBD and both neurodegenerative and psychiatric disorders. Lewy body diseases and post-traumatic stress disorder had the most shared polygenic risk pathways in neurological and psychiatric disorders, respectively. Two pathways, the serotonin transport pathway and the chaperone-mediated autophagy pathway, showed the strongest association with iRBD, and gene-based rare variants analyses revealed five genes associated with iRBD: GBA1 , PLEKHM1 , LRP2 , P2RX1 , and HAP1. Subsequent analysis of these genes in Parkinson’s disease and dementia with Lewy bodies replicated several associations. Together, these findings provide novel insights into the shared genetic architecture underlying iRBD, neurodegenerative disorders, and psychiatric traits, with implications for early identification and mechanistic understanding.


  • Open Access

    When Proteins Go MAD—Misfolded, Amplified, Detected: Advances in α-Synuclein Pathophysiology and RT-QuIC Detection

    by Naďa Labajová, Adam Polák, Ondrej Cehlár, Pavle Križan, Jozef Hritz, Martin Kolisek, Matej Škorvánek, Rostislav Škrabana, Branislav Kovačech, Norbert Žilka

    Α-Synuclein (α-Syn) aggregation and fibrillation are pathological hallmarks of several neurodegenerative disorders, collectively termed synucleinopathies. The misfolded α-Syn protein exhibits a prion-like seeding behavior, promoting misfolding, intracellular spread, and progressive neurodegeneration. Recent advances in structural biology have revealed critical insights into the conformational heterogeneity of α-Syn aggregates and their strain-specific properties across distinct synucleinopathies. In parallel, significant progress has been made in biomarker development, particularly with the arrival of seed amplification assays. Among these, Real-Time Quaking-Induced Conversion (RT-QuIC) has emerged as a highly sensitive, specific, and scalable method for detecting pathogenic α-Syn species in cerebrospinal fluid and other tissues. This review summarizes the latest findings from structural studies on α-Syn oligomers and aggregates, their relevance to disease mechanisms, and highlights RT-QuIC as the most clinically advanced and rapidly evolving assay. We discuss its potential for early, biomarker-driven diagnostics, patient stratification, and clinical implementation.

  • MDS PD e‐Diary: A New Patient‐Centered Digital Tool in Development for People with Parkinson's Disease

    by Pablo Rábano‐Suárez, Mariana H.G. Monje, Joaquín A. Vizcarra, Serene S. Paul, Sabela Avión, Michael Morse, Matej Skorvanek, Michelle H.S. Tosin, Rebecca L.M. Fuller, Travis H. Turner, et al.

    Background: There is a need to better evaluate Parkinson's disease (PD) impact on daily lives of People with Parkinson's (PwP). Objectives: To conceptualize a novel digital tool, the MDS PD e‐Diary that has been commissioned by the International Parkinson's disease and Movement Disorders Society. Methods: Using a modified Delphi methodology, we sought consensus among key stakeholders (PwP, care partners, PD specialists, industry, regulatory representatives) through online questionnaires, focus groups, and a broad community survey. Results: The consensus resulted in a multiplatform patient‐reported outcome tool to track PD progression. It includes an Item Bank of symptoms and activities featuring two interconnected user modes. The personal mode is a customizable self‐tracking tool that allows data sharing with professionals to improve standard care. The research mode employs a predefined responsive item to enhance research and clinical trials. Conclusion: The MDS PD e‐Diary was designed to capture PD progression and its impact on PwP lives, potentially transforming research and clinical practice. Its further development and validation processes are underway.